News about SOLTI

A biomarker helps select the patients who respond best to patritumab deruxtecan in breast cancer

A study promoted by SOLTI and published in Nature Communications describes the tumour biology associated with the activity of the drug patritumab der1

Clínic Barcelona

Research June 30 2021

A study explains how chemotherapy works in young women with low-risk hormone-sensitive breast cancer

Researchers from Hospital Clínic-IDIBAPS have shown for the first time that the benefit of chemotherapy in premenopausal patients with low-risk hormo1

Clínic Barcelona

Research June 14 2021

Launch of a pioneering clinical trial to validate the efficacy of immunotherapy in 29 types of tumour

The ACROPOLI clinical trial is being launched. It is a pioneering, nationwide research study that aims to assess the efficacy of immunotherapy in 291

Clínic Barcelona

Research March 29 2021

A molecular classification predicts the prognosis and the benefit of a cell cycle inhibitor in metastatic breast cancer

In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity of1

Clínic Barcelona

Research December 11 2019

A new biological treatment could replace chemotherapy in patients with aggressive breast cancer

Today the results of the phase 2 CORALLEEN clinical trial, promoted by the international academic group SOLTI, have been presented. The study, publis1

News about SOLTI

A biomarker helps select the patients who respond best to patritumab deruxtecan in breast cancer

A study explains how chemotherapy works in young women with low-risk hormone-sensitive breast cancer

Launch of a pioneering clinical trial to validate the efficacy of immunotherapy in 29 types of tumour

A molecular classification predicts the prognosis and the benefit of a cell cycle inhibitor in metastatic breast cancer

A new biological treatment could replace chemotherapy in patients with aggressive breast cancer

Subscribe to the Newsletter of Clínic